Clinical Trial Update: STI571 in Treating Patients With Accelerated Phase Chronic Myelogenous Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating STI571 (imatinib) in patients with accelerated-phase chronic myeloid leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia
• Chronic Myeloid Leukemia Accelerated Phase

Drugs mentioned

• STI571 (imatinib)

Snippet

Sponsor: Novartis | Conditions: Leukemia | Phase 2 | Status: COMPLETED